Osimertinib Plus Chemo Approved for EGFR-mutated NSCLC
With the new approval, patients now have the option of combination treatment or osimertinib monotherapy.
Source: medscape.com
Page 7 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nsclc Today - Breaking & Trending Today
Rigel takes on US marketing of Blueprint's Gavreto
Blueprint Medicines Corp. found a new U.S. commercialization home for Gavreto (pralsetinib) through an agreement with Rigel Pharmaceuticals Inc. potentially worth $117.5 million, now that Roche Holding AG has relinquished all rights.
Source: bioworld.com
#VisualAbstract: Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer
1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed a significant survival benefit with SBRT in comparison to patients with breast cancer. Evidence Rating Level: 1 (Excellent) Study Rundown: Most patients with metastatic breast cancer develop resistance to systemic therapy. Stereotactic body radiotherapy (SBRT) is a
Source: 2minutemedicine.com
RATIONALE-315 Data Support Perioperative Tislelizumab Plus Neoadjuvant Chemo in Resectable NSCLC
Neoadjuvant tislelizumab plus platinum-based doublet chemotherapy followed by surgery and adjuvant tislelizumab demonstrated efficacy in resectable non–small cell lung cancer.
Source: onclive.com
Reflex Molecular Testing May Enhance Targeted Therapy Benefit in Early-Stage Lung Cancer
Jobelle Baldonado, MD, highlights the emergence of targeted therapies and the need for reflex-ordered molecular testing in early-stage lung cancer.
Source: onclive.com